Most of the protein kinase inhibitors being developed are directed toward the adenosine triphosphate (ATP) binding site that is highly conserved in many kinases. A major issue with these inhibitors is the specificity for a given kinase. Structure determination of several kinases has shown that protein kinases adopt distinct conformations in their inactive state, in contrast to their strikingly similar conformations in their active states. Hence, alternative assay formats that can identify compounds targeting the inactive form of a protein kinase are desirable. The authors describe the development and optimization of an Immobilized Metal Assay for Phosphochemicals (IMAP™)-based couple™d assay using PDK1 and inactive Akt-2 enzymes. PDK1 phosphorylates Akt-2 at Thr 309 in the catalytic domain, leading to enzymatic activation. Activation of Akt by PDK1 is measured by quantitating the phosphorylation of Akt-specific substrate peptide using the IMAP assay format. This IMAP-coupled assay has been formatted in a 384-well microplate format with a Z′ of 0.73 suitable for high-throughput screening. This assay was evaluated by screening the biologically active sample set LOPAC™ and validated with the protein kinase C inhibitor staurosporine. The IC 50 value generated was comparable to the value obtained by the radioactive 33 P-γ-ATP flashplate transfer assay. This coupled assay has the potential to identify compounds that target the inactive form of Akt and prevent its activation by PDK1, in addition to finding inhibitors of PDK1 and activated Akt enzymes. (Journal of Biomolecular Screening 2004:309-321) 
INTRODUCTION
P ROTEIN KINASES PLAY AN IMPORTANT ROLE in many signaling events that control the activation, growth, and differentiation of cells in response to extracellular mediators and to changes in the environment. Aberrant protein kinase expression or functioning is a cause or consequence of many human diseases, including cancer, diabetes, rheumatoid arthritis, psoriasis, and fibrosis. [1] [2] [3] For this reason, protein kinases are a focus of small-molecule drug discovery efforts at many pharmaceutical companies. This effort has been reinforced by the recent approval of 3 protein kinase inhibi-tors for clinical use in the treatment of various cancers: Gleevec (STI571), Fasudil (Y 27632), and Iressa (ZD 1839). 2, 4 Protein kinases comprise the second most important targets for drug discovery after G-protein-coupled receptors. More than 500 genes encoding protein kinases have been identified in the near-completed sequence of the human genome. 5 Methods to identify kinase inhibitors by high-throughput screening (HTS) have evolved rapidly in recent years. An important aspect is the availability of homogeneous assays based on fluorescence readouts. [6] [7] [8] [9] [10] This has led to extensive efforts to develop kinase inhibitors for the treatment of a wide range of diseases, and more than 30 such agents are now in clinical trials.
Most of the protein kinase inhibitors that are now in clinical development are directed toward the adenosine triphosphate (ATP) binding site. These inhibitors are frequently detected by screening for inhibition of kinase activity in biochemical assays. Recent insights into the biochemistry of kinase action have led to the recognition of the fact that certain kinases have distinct active and inac-tive (nonphosphorylated) conformations. 11 The catalytic domains of different kinases adopt strikingly similar structures when they are active. By contrast, crystal structures of inactive kinases have revealed plasticity in the kinase domains, which allows the adoption of distinct conformations in response to interactions with specific regulatory domains, proteins, or posttranslational phosphorylations. Inhibitors that specifically target the inactive forms of 3 kinases (e.g., p38 MAP kinase, Tie-2, and bcr-abl) have been reported. [12] [13] [14] Gleevec, which is an inhibitor of bcr-abl kinase and approved for the treatment of chronic myelogenous leukemia, specifically targets the inactive form of abl kinase. 15, 16 One of the unusual features of Gleevec bound to the unphosphorylated protein is that it inhibits Abl activation by blocking autophosphorylation. Another feature that all 3 compounds have in common is that the inhibitor is bound to the conformation that has very low affinity for ATP. Based on these examples, alternative assays are being developed to select compounds that would bind to the inactive form of the kinase so as to sequester the molecule in a state that cannot participate in signal transduction.
We sought to develop a high-throughput homogeneous coupled assay that is generally applicable to kinase targets using activation of Akt kinase by 3′-phosphatidyl-inositol-dependent kinase 1 (PDK1) as a model system. Akt, also known as protein kinase B (PKB), is the cellular homologue of the viral oncogene v-Akt of the transforming murine leukemia virus Akt-8. 17 Akt/PKB is an important regulator of cell survival, cell proliferation, and insulin signaling. [18] [19] [20] [21] There are 3 mammalian isoforms of this serine/ threonine kinase: Akt-1, Akt-2, and Akt-3. Each isoform is composed of 3 distinct and conserved domains: an N-terminal pleckstrin homology domain (PH domain), which binds to membrane inositol phospholipids; a catalytic protein kinase domain; and a short carboxy-terminal hydrophobic region.
Akt is activated by and dependent on multisite phosphorylation. One main site of phosphorylation is a threonine residue within the activation T-loop. In Akt-1, this is Thr 308, and in Akt-2, it is Thr 309. Phosphorylation at this threonine residue causes a charge-induced change in conformation, allowing substrate binding and greatly elevated rate of catalysis. 22 In resting cells, the activation/phosphorylation level of Akt is very low, but upon mitogenic stimulation, the level increases rapidly. PDK1 is the enzyme that phosphorylates Akt and other members of the AGC family of ser/thr kinases. 23 PDK1 contains an N-terminal catalytic domain and a C-terminal PH domain that interact with phosphatidylinositol-3-phosphate (PIP3) lipids. The activation of Akt by PDK1 is greatly enhanced in the presence of lipid vesicles containing PIP3 lipids. 23 PDK1 phosphorylates Akt in vitro, and overexpression of PDK1 in cells leads to elevated Thr 308 (Thr 309 in Akt-2) phosphorylation. It is believed that PIP3 lipids concentrate both PDK1 and Akt onto a lipid micelle surface in vitro and colocalize these proteins at membranes in vivo, enabling phosphorylation of Akt by PDK1. In cells in which PDK1 has been genetically disrupted, Akt is unresponsive to mitogenic stimulation as a consequence of a loss of Thr 308 phosphorylation. 24 In this article, we describe the development of a homogeneous coupled assay that is amenable for HTS. The general methodology that we have adapted for the development of this coupled assay is based on the principle of the Immobilized Metal Assay for Phosphochemicals (IMAP™) (Mole™cular Devices, Sunnyvale, CA). This is a fluorescence polarization (FP) assay based on the affinity capture of phosphorylated peptides. 6,10 IMAP uses fluorescein-labeled peptide substrate that, upon phosphorylation by a protein kinase, binds to nanoparticles that are derivatized with trivalent metal complexes. This metal-phospholigand complex tumbles slowly in solution, generating a high polarization value, whereas the nonphosphorylated fluorescein-labeled substrate tumbles rapidly in solution, generating a low polarization value. The coupled assay that we describe here has the advantage of identifying compounds that bind to the different activity states/conformations of a target kinase in addition to identifying compounds that inhibit the upstream kinase, PDK1, and the target enzyme Akt.
MATERIALS AND METHODS

Materials
IMAP assays were done in polystyrene 96-or 384-well black plates purchased from Matrix (Hudson, NH). Dithiothreitol (DTT), ATP, staurosporine, imidazole, ethylenediaminetetraacetic acid (EDTA), and a library of biologically active compounds (LOPAC™) were purchased from Sigma-Aldrich (St. Louis, MO). DMSO and protease inhibitor tablets were purchased from Fischer Scientific (Fair Lawn, NJ) and Calbiochem (La Jolla, CA), respectively. Synthetic phospholipids 1,2-dioleoyl-sn-glycerol-3phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycerol-3phospho-L-serine (DOPS) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL), and the PIP3 lipids were purchased from Biomol Research Laboratories (Plymouth Meeting, PA). The IMAP Akt assay kit-which includes 400× IMAP beads, 5× binding buffer (~pH 5.5), and kinase reaction buffer (~pH 7.2)-was obtained from Molecular Devices (Sunnyvale, CA). The fluorescein-labeled Akt-specific substrate peptide of sequence Gsk-3α-derived 5-FAM-RARTSSFAEPG, the corresponding phosphorylated peptide product, and the biotinylated Akt-specific substrate peptide of sequence Bio-ahx-RPRAASF were synthesized at Synpep (Dublin, CA). Peptides were dissolved in DMSO to a concentration of 1 mM, and the 96-well streptavidin-coated flashplates and 33 P-γ-ATP (3000 Ci/mmol) were purchased from PerkinElmer (Boston, MA). All fluorescence readings were performed on an Analyst™ HT from Molecular Devices as previously described. 8 Data analysis was performed with GraphPad Prism (San Diego, CA).
Cloning, expression, and purification of PDK1
Plasmid DNA-containing human PDK1 cDNA (identified from a human cDNA library) was obtained from Dr. Dhanasekharan at Temple University Medical School, Philadel-phia. This plasmid was used as a template for generating appropriate PCR fragments for subcloning into the baculovirus vector. Oligonucleotide primers were designed to isolate full-length PDK1 cDNA with a myc (9E10) epitope tag at the N-terminus. PCR primers were designed to add a BglII restriction site to the 5′end and an EcoRI site to the 3′-end. PCR fragments were digested with BglII and EcoRI restriction enzymes, extracted from agarose gels and used for subcloning into the BamHI-and EcoRI-digested pAcG2T plasmid vector from Pharmingen (San Diego, CA). The resulting recombinant plasmid was completely sequenced to verify the PDK1 coding and junction sequences. Recombinant baculovirus stocks expressing glutathione-S-transferase (GST)tagged PDK1 were isolated and amplified, and titers were determined by Cell Trends, Inc. (Middletown, MD).
GST-PDK1 was purified from Sf9 cells using the recombinant baculovirus stock. Cell pellets from 10-L cultures were resuspended in 300 mL of phosphate-buffered saline (PBS), 1 mM EDTA, 1 mM DTT, 1 mM AEBSF (PMSF), and 1:1000 of Calbiochem Protease Cocktail III, pH 7.5 (buffer A), and lysed by microfluidization. The lysates were centrifuged for 1 h at 40,000 rpm in a Ti45 rotor. The supernatant was loaded onto a 10-mL glutathione-4B column equilibrated in buffer A. The loaded sample was washed with 50 mM Tris, 0.15 M NaCl, and 1 mM DTT, pH 8.0 (buffer B), and then eluted with a gradient of buffer B + 20 mM reduced glutathione, pH 8.0. The eluted fractions were~70% pure and contained < 10% of GST cleaved nonspecifically from the fusion protein. A size exclusion chromatography step using an S-200 column equilibrated in 50 mM Tris (pH 7.5), 0.2 M NaCl, 1 mM DTT, 0.6 mL Protease Inhibitor Cocktail V, and 1 mM EDTA (buffer C) was used to further purify the GST-PDK1. Eluted fractions (> 90% pure) were pooled based on the purity observed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and frozen at -80°C. This protocol provides~10 to 15 mg GST-PDK1 with greater than 90% purity. The observed mass by liquid chromatography-electron spray mass spectrometry (LC-ESMS) was 90,780 Da.
Cloning, expression, and purification of Akt-2
A plasmid containing full-length human Akt-2 cDNA, obtained from Joseph R. Testa at Fox Chase Cancer Center in Philadelphia, was used as a template to generate an appropriate PCR fragment for subcloning into the baculovirus vector. Appropriate oligonucleotide primers were designed to PCR amplify full-length human Akt-2 coding sequences with a BamHI restriction site at the 5′-end and an EcoRI site at the 3′-end and subcloned into the pBlueBacHis2B vector (Invitrogen, Carlsbad, CA). The resulting plasmid encodes Akt-2 coding sequences fused to the His 6 tag and an antiexpress antibody epitope-tag at the N-terminus. This construct was sequenced to verify the junction and coding sequences and used for generating recombinant baculovirus stocks. Derivation of recombinant baculovirus stocks, amplification of virus stocks, and titer determinations were carried out at Cell Trends, Inc. (Middletown, MD).
Baculovirus stocks expressing His 6 -tagged Akt-2 protein were used to infect large-scale Sf9 cells. A 10-L fermentation produced 110 g of wet cell pellet. To this pellet was added 400 mL of 50 mM Tris, 50 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT, and 1:500 dilution of Calbiochem Protease Cocktail III, pH 7.8. The resuspended cells were lysed by microfluidization and centrifuged using a Ti45 rotor for 1 h at 4°C at 40,000 rpm. The supernatant fraction was loaded onto a 40-mL Pharmacia QFF column and washed with 20 mM Tris-HCl (pH 7.8), 50 mM NaCl, 10% glycerol, 10 mM β-mercaptoethanol, and 1:1000 dilution of Calbiochem Protease Cocktail III (buffer A). Protein fractions were eluted by developing a gradient using buffer A + 0.5 M NaCl. Peak fractions were eluted with~0.25 M NaCl, providing a~1000mg total protein that was~10% pure. The partially purified His-Akt-2 fraction was further purified by adding imidazole to a final concentration of 20 mM and loading the sample onto a 10-mL Qiagen Nickel column equilibrated in 20 mM Tris, 0.3 M NaCl, 5 mM β-mercaptoethanol, and 20 mM imidazole, pH 7.8 (buffer B). Purified fractions were eluted by developing an imidazole gradient 20 to 200 mM in buffer B. Approximately 17 mg of His-Akt-2 was obtained at > 90% purity.
Western blotting
Protein samples were electrophoresed on 10% Bis-Tris NuPAGE polyacrylamide gels (Invitrogen), transferred to 0.45µm nitrocellulose membranes (Invitrogen), and probed with antibodies as described previously. 25 Total Akt and phospho-Akt-Ser 473 and phosphor-Akt-Thr 308 antibodies were obtained from Cell Signaling Technology (Beverly, Massachusetts). The protein/ antibody complex was visualized using an anti-rabbit (CST) IgG horseradish peroxidase-linked antibody from Cell Signaling Technology and the Electro Chemi Luminescence western blotting detection system (Amersham, Chicago).
Phospholipid vesicle preparation
Synthetic phospholipids blend (25 mg) ( 
, 1:1 wt%) was dissolved by vortexing for 5 min in 1 mL of degassed 10 mM HEPES, 1 mM EGTA, and 1 mg/mL bovine serum albumin (BSA) buffer to a final concentration of approximately~33 mM. Then, 300 µg of PIP3 lipid was resuspended in 950 µL of degassed 10 mM HEPES, 1 mM EGTA, and 1 mg/mL BSA buffer by gently vortexing and/or pipetting up and down several times. The final concentration of the PIP3 lipid was~300 µM. Small unilamellar vesicles were prepared by mixing 50 µL of DOPC/DOPS to the~300-µM/950-µL PIP3 lipids at 4°C for 2 h, followed by sonication in a bath sonicator for 20 min on ice, without aerosolizing or foaming the sample. The resulting solution was clearer and more translucent than before sonication. The resulting PIP3/DOPC/DOPS phospholipid vesicles were aliquotted in amber microfuge tubes and overlaid with argon or nitrogen to reduce oxidation. The lipid vesicles were stored in -70°C and used within 1 month.
Flashplate assay
A streptavidin-coated flashplate assay format was developed initially that used human GST-PDK1 as the activating enzyme and inactive human Akt-2 protein as the activatable enzyme. A biotinylated peptide of sequence Bio-ahx-RPRAASF that is specifically phosphorylated by Akt was used as a substrate. Briefly, the assays were performed in 96-well plates and comprised the following reagents: 1 µM biotinylated peptide, 200 ng inactive Akt-2 protein, 50 ng of GST-PDK1, 0.25 µCi 33 P-γ-ATP, 2 µM unlabeled ATP, 50 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 1 mM DTT, 0.01% Triton X-100, 2% DMSO, and 0.1 mM sodium orthovanadate. Following a 2-h incubation at room temperature, 200 µL of stop solution containing 1 mM ATP and 5 mM EDTA was added to each well to terminate the reactions. Then, 200 µL of the reactions was transferred to streptavidin-coated flashplates and further incubated for 1 h at room temperature, followed by 3 washes with PBS. Plates were then counted using TopCount (PerkinElmer, Boston).
IMAP assay
The IMAP Akt-2 coupled assay was formatted using 25-µL reaction volumes consisting of 5 µL compound; 10 µL PDK1, Akt-2, and peptide substrate; and 10 µL ATP and PIP3 lipids. Compounds were diluted with DMSO in kinase assay buffer such that the final concentration of DMSO was 2%. Positive controls contained 2% DMSO, and negative controls contained staurosporine at 10 µM in 2% DMSO. Enzymes, substrate, ATP, and PIP3 lipids were prepared in kinase reaction buffer consisting of 10 mM Tris-HCl (pH 7.2), 10 mM MgCl 2 , 0.1% BSA, 0.05% NaN 3 , and 1 mM DTT. The final concentrations of PDK1 and Akt-2 were 20 and 50 ng/well, respectively, unless otherwise stated. The final concentrations of substrate, ATP, and PIP3 lipids were 100 nM, 2 µM, and 5 µM, respectively, unless otherwise stated. Following a 2-h incubation at room temperature, the IMAP binding reagent was prepared in 1× binding buffer to a concentration of 2× IMAP beads, and 30 µL was added to each well to stop the reaction. After incubation for 30 min at room temperature, the fluorescence polarization was measured on an Analyst™ multimode fluorescence plate reader at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. The settings of the instrument were as described previously. 8
RESULTS AND DISCUSSION
Phosphorylation of Akt-2 by PDK1
Previous studies have shown that the Akt-1 purified from Sf9 cells, following infection with recombinant baculovirus express-ing Akt-1, is enzymatically not active even though it is phosphorylated at Ser 473 and reactive with antibodies raised against phospho-Ser 473 Akt protein. 25 The Sf9-expressed Akt-1 protein lacked phosphorylation at Thr 308, and coexpression of the membrane-targeted PI-3-kinase catalytic subunit or treatment of Sf9 cells with okadaic acid led to a significant increase in phosphorylation at Thr 308 and the enzymatic activity. These results confirmed studies from other laboratories that phosphorylation at Thr 308 is critical for the enzymatic activation of Akt-1. 26 The enzyme that phosphorylates Akt at the Thr 308 position is PDK1, which contains an N-terminal catalytic domain and a C-terminal PH domain that interacts with PIP3 lipids. For the development of the coupled assay, we have used Akt-2 full-length protein purified from Sf9 cells, following infection with recombinant baculovirus expressing Akt-2, as a fusion protein containing His 6 tag and an antiexpress epitope tag at the N-terminus. As observed with the Akt-1 protein, Akt-2 purified from Sf9 cells lacked phosphorylation at Thr 309 and is enzymatically inactive. To confirm that GST-PDK1 phosphorylates Akt-2 at the Thr 309 site, inactive Akt-2 protein was incubated with and without PDK1 in the presence of cold ATP and 10-µM PIP3 lipids for 60 min, and the protein was electrophoresed on 6% polyacrylamide gels followed by blotting onto nitrocellulose membranes. Membranes were probed with antibodies raised against total Akt, phospho-specific (Thr 308) Akt, or phospho-specific (Ser 473) Akt. These antibodies recognize both Akt-1 and Akt-2 phosphorylated at the threonine residue in the T-loop and Ser 473 in the C-terminal hydrophobic tail. As shown in Figure 1 , Akt-2 protein purified from Sf9 cells showed strong reactivity with Ser 473 phospho-specific Akt antibodies, and following incubation with PDK1, there was no further increase in phosphorylation. However, as expected, in the absence of PDK1, Akt-2 protein showed weak reactivity with phospho-Thr 308-specific Akt antibodies, and following incubation with PDK1, there was a significant increase in phosphorylation at the Thr 309 position. . Akt-2 protein purified from Sf9 cells (300 ng) was incubated with and without glutathione-S-transferase (GST)-PDK1 (50 ng) in the presence of cold adenosine triphosphate (ATP) and phosphatidylinositol-3-phosphate (PIP3) lipids for 60 min, and the proteins were separated on 6% polyacrylamide gels followed by blotting onto nitrocellulose membranes. Membranes were probed with antibodies raised against total Akt, (Thr308) phospho-specific Akt, or (Ser 473) phospho-specific Akt.
Evaluation of coupled assay by flashplate format: requirement of PDK1 for activation of Akt-2 and the specificity of peptide substrate in the coupled assay
Next we evaluated the enzymatic activity of Akt-2 activated by PDK1 using 33 P-γ-ATP and a biotinylated Akt-specific substrate peptide. In this format, inactive Akt-2 protein purified from Sf9 cells was incubated with GST-PDK1 for 30 min in the presence of cold ATP (2 µM), followed by addition of 1 µM biotinylated Aktspecific substrate peptide and 33 P-γ-ATP (0.25 µCi/reaction). Reaction mixtures were incubated for different lengths of time, and phosphorylation of biotinylated peptide substrate was measured following transfer to streptavidin-coated flashplates. After further incubation for 1 h at room temperature to allow binding of biotinylated peptide to the streptavidin, plates were washed 3 times with wash buffer containing 1 mM cold ATP and 5 mM EDTA and counted using the TopCount instrument. Appropriate controls were included to evaluate the requirement for various components of the coupled assay such as PDK1, Akt-2, peptide substrate, and lipids. Specifically, the following controls were included (1) no PDK1, (2) no Akt-2, and (3) no peptide. As shown in Figure 2A , Akt-2 activation was dependent on PDK1, as the protein alone had very low kinase activity and PDK1 alone fails to phosphorylate the peptide substrate. These results also indicate that this assay format is not detecting phosphorylation of Akt-2 by PDK1, as the counts captured in the absence of Akt-specific peptide substrate are close to background value. Similarly, in the absence of PIP3 lipids, there was very little activation of Akt-2 (results not shown).
This radioactive 33 P-based coupled assay involved carrying out the reactions in regular 96-well plates, stopping the reactions, and transferring the reagents to streptavidin-coated flashplates. To see if the activation reaction could be carried out in the streptavidincoated flashplates, without the transfer step, the reaction components were assembled in flashplates and incubated for 90 min before washing 3 times and counting. Experimental design was similar to the experiment described above. Results shown in Figure  2B indicated that there was no time-dependent increase in the phosphorylation of biotinylated peptide under these conditions. A possible reason for this could be that the biotinylated peptide is bound to the walls of the streptavidin-coated flashplates and not easily accessible for phosphorylation by activated Akt-2, as the enzymes PDK1 and Akt-2 are also sequestered by the lipid vesicles. The transfer assay format was not truly high throughput and therefore not easily amenable for the screening of a large number of compounds. Hence, we decided to investigate alternate assay formats to facilitate HTS of compounds.
IMAP assay format for activation of Akt-2 by PDK1
In the initial experiments, the requirement of PDK1 and PIP3 lipids for activation of Akt-2 and the specificity of the peptide substrate used were determined using the IMAP assay format. Inactive Akt-2 protein and GST-PDK1 were incubated in the presence of fluorescein-labeled substrate peptide (Gsk-3α-derived) (5-FAM-RARTSSFAEPG), 5 µM cold ATP, and 10 µM PIP3 lipid for 2 h, followed by addition of IMAP binding buffer. Appropriate controls were included, such as no PDK1, no Akt-2, and 10 µM staurosporine. Akt-specific substrate peptide or Fl-tagged CDK4specific substrate peptide (5-FAM-RPPTLSPIPHIPR) was also included in a separate set of reactions along with these controls. Delta mP (∆mP) values (mP of fluoresceinated phosphorylated product bound to beads minus mP of fluoresceinated substrate in the presence of the beads) were calculated for each panel. Results shown in Figure 3A indicate that the activity seen with PDK1 alone and Akt-2 alone was similar to background levels (~20-40 mP), which were determined with complete reactions containing PDK1, Akt-2, and PIP3 lipids in the presence of 10 µM staurosporine. An increase in ∆mP values to 190 was seen only when Akt-2 was incubated with PDK1 in the presence of ATP, substrate peptide, and PIP3 lipids. There was no increase in ∆mP values using CDK4 peptide substrate, confirming the lack of phosphorylation of this peptide as expected. These results are consistent with the activation observed using the radiometric flashplate assay.
Next, the dependency on PIP3 lipids for activation of Akt-2 by PDK1 was determined by incubating Akt-2 with a constant amount of PDK1 in the presence of different concentrations of PIP3 lipids. Reactions were stopped at different time intervals by adding IMAP beads and measuring ∆mP (mP of the complete reaction minus the mP of reactions in the presence of 10 µM staurosporine) values as described above. Complete reactions in the presence of 10 µM staurosporine served as negative controls. As shown in Figure 3B , in the absence of PIP3 lipids, there was very little activation of Akt-2 by PDK1, indicating that PIP3 lipids are required for the activation of Akt-2 by PDK1. Optimal activation of Akt-2 required 5 to 10 µM PIP3 lipids. These results agree with those observed using the 33 P-based flashplate assay format and suggest that IMAP is a valuable assay format that gives results similar to a conventional radiometric assay format.
Dose response of PDK1 and Akt-2 in the coupled assay and progress curve analysis
In the next set of experiments, a constant amount of Akt-2 (either 25 or 50 ng) was incubated with varying concentrations of PDK1 (from 2-20 ng) and the reactions stopped at different intervals of time to measure ∆mP values. The negative control was determined by running complete reactions in the presence of 10 µM staurosporine. To analyze progress curves, an integrated expression was derived, predicated on the assumption that activation of Akt-2 by PDK1 is first order with respect to the former in the presence of excess ATP-that is,
where [Akt′] is activated Akt at time t, [Akt] 0 is the initial concentration of unactivated Akt, and k 1 is the apparent rate constant of activation under the given reaction conditions. It was also assumed that phosphorylation of the target peptide is first order with respect to both peptide and activated Akt-2 concentration:
where k 2 is the second-order rate constant (k cat K m ), and [pep] 0 is the initial concentration of peptide. Substituting (1) into (2) and integrating, we get
Evaluating over the interval 0 to t (i.e., [ (6) normalizing to a fraction of the substrate converted, as indicated by change in the fluorescence polarization of a sample using a conversion factor (Ψ) based on the following standard curve:
The mP units, corrected against negative controls (∆mP), were fitted to (7) using MacCurve Fit 1.5.2 (Kevin Raner Software, Victoria, Australia). The R 2 values for equation (7), fitted using nonlinear regression, were better than 0.98 for all data sets. Results shown in Figure 4A (25 ng of Akt-2) and 4B (50 ng of Akt-2) indicate that activation of Akt-2 is both dose and time dependent with respect to PDK1 concentration. As expected with higher concentrations of PDK1 (20 ng), activation was maximal at 150 min, whereas with 5 ng of PDK1 and 25 ng of Akt-2, maximal activation required incubation for > 200 min. Similarly, 2 ng of PDK1 required longer incubation times for activation of Akt-2 at both 25-and 50-ng protein concentrations. Figure 4C shows that there was a linear relationship with respect to the amount of PDK1 (from 2-30 ng) for activation of a constant amount of Akt-2 (50 ng). Maximal activation was achieved at 30 ng of PDK1, and there was no further increase in Akt-2 activation with higher concentrations of PDK1.
In a similar experiment, a constant amount of PDK1 (either 20 or 40 ng/reaction) was incubated with increasing concentrations of Akt-2 and the reactions stopped at different intervals of time to measure ∆mP values as described above. Results shown in Figure  5A , B indicate that activation is both dose and time dependent on Akt-2 concentration. As seen above with PDK1, using higher concentrations of Akt-2 (400 ng of Akt-2 with 20 ng of PDK1), maximal activation occurred by 120 min because the maximum ∆mP that could be detected under the assay conditions is around 280, whereas with lower amounts of Akt-2 (50 ng of Akt-2 with 20 ng of PDK1), maximal activation required > 4 h of incubation. Figure  5C shows a linear relationship with respect to the amount of Akt-2 (from 12.5-400 ng) using a constant amount of PDK1 (20 ng). Maximal activation was achieved at 200 ng of Akt-2, and there was no further increase in activation with higher concentrations of Akt-2. The optimal amounts of Akt-2 and PDK1 used for the standard assay conditions were 50 and 20 ng/well, respectively, and the time of incubation was 120 min.
Titration of lipids, ATP, and peptide substrate optimal for the activation of Akt-2 by PDK1
Based on the fact that the IMAP beads bind phosphate groups, not only will the beads bind the phosphorylated peptide product, but they will also bind ATP and PIP3 lipids. Therefore, one must determine the concentrations at which ATP and PIP3 lipids begin to compete for binding to the beads, reducing the assay signal and performance. To determine the optimal amount of PIP3 lipids required for the coupled assay, increasing concentrations of PIP3 lipids were added to the reaction mixtures containing 20 ng of PDK1 and 50 ng of Akt-2 and incubated for 120 min. A dosedependent increase in activation of Akt-2 with increasing concentrations of PIP3 lipids was observed (results not shown). For the standard reactions, 5-µM lipids were used as higher amounts of PIP3 lipids (20 µM and above) would compete with the phosphorylated peptide substrate for binding to IMAP beads. Next, we determined the optimal concentrations of ATP in the coupled assay. ATP concentrations were varied from 2 to 50 µM in the presence of 20 ng PDK1 and 50 ng Akt-2 for 120 min. Maximal activation of Akt-2 by PDK1 required 10 µM ATP (results not shown). Because the compounds we are interested in finding are ATP competitors and because ATP also binds to IMAP beads, the concentration of ATP used in the final assay conditions was 2 to 5 µM. In agreement with previous observations, concentrations above 10 µM ATP led to a reduction in ∆mP values due to binding of ATP to IMAP beads. 8 Titration of fluorescein-labeled Akt-specific substrate was examined in the coupled assay by varying the concentration of peptide from 5 to 10,000 nM. When high concentrations of peptide are used, more enzyme and ATP will be needed to convert the substrate to product, and fractional conversion of substrate may be less than optimal. The optimal concentration of the peptide for the coupled assay is 100 nM, and with higher concentrations of the peptide, the ∆mP values decreased. Because the substrate serves dual functions, 2 aspects need to be considered for an optimal substrate concentration in the assay. Besides serving as a substrate for the kinase, it also carries a fluorophore to obtain the fluorescence signal. A threshold concentration of the peptide is required to obtain a reliable FP value. An additional benefit of running at a 100-nM concentration is that it is high enough to minimize fluorescent compound interference.
Optimization of IMAP bead concentration and volume
When screening compounds, it is advantageous to streamline the number of additions and maintain similar addition volumes to keep the appropriate timing loops when multidispensing. With this in mind, we looked at reducing the volume of the beads added to stop the reactions, keeping the reaction volumes at 25 µL. To determine the smallest volume of IMAP beads that could be added to the reaction mix without compromising the signal detection, the beads were prepared at both 1× and 2× concentration, diluted in 1× binding buffer and added to the reaction mixtures at various vol-umes. Results shown in Figure 6 indicate that 40 µL of bead volume was the minimum volume required to detect the optimal signal at 1× bead concentration, and 30 µL was the minimum volume required for signal reading at 2× bead concentration. In subsequent experiments, 30 µL of 2× IMAP beads in 1× binding buffer was used to stop the reactions and read the signals.
Calibration curves for substrate/product mixture
A mix of fluoresceinated substrate and fluoresceinated phosphorylated product was incubated with IMAP beads to allow calculation of the percentage of product formed during an enzymatic reaction. The peptides were prepared to a combined final concentration of 100 nM made in kinase buffer with 1 mM DTT, 5 µM ATP, and 10 µM PIP3 lipids by varying the ratio of substrate to product. The amount of each peptide was varied to generate a curve from 0% product and 100% substrate to 100% product and 0% substrate in a total volume of 25 µL. Then, 30 µL of 2× beads was added to the reaction mixtures, and mP values were deter-mined as described previously. 8 The ∆mP values were plotted as a function of percent fluoro-phospho peptide in the reaction mixture (results not shown). 8 The results indicated that the linearity of the assay extends up to 100% of the phosphorylated peptide. In the optimal assay conditions of the coupled assay, the amount of product 
Signal stability: overnight reading
The stability of the signal of the stopped reaction was assessed 30 min after adding IMAP beads and subsequently after incubating overnight at room temperature. A representative experimental result is shown in Figure 7 . In this experiment, different volumes of 2× beads were added to stop the coupled reactions. The plates were read once after stopping the reactions with IMAP beads and incubating the plate for 30 min. The same plate was then read again the following day after overnight incubation. Results shown in Figure  7 indicate that plates read 24 h later showed no change in ∆mP readings.
Compound evaluations: LOPAC plate summary
The coupled assay using IMAP technology can be easily applied to HTS. We tested 640 bioactive compounds (the LOPAC library) dispensed in 384-well plates. The LOPAC set from RBI (lot #TOY 599A) was dissolved in DMSO to a concentration of 2 mg/ mL. Compounds were diluted in kinase buffer to a final concentration of 2 µg/mL in 2% DMSO, and 5 µL was added to each well. The compounds were arrayed as a mixture of 8 compounds in each well and dispensed in 384-well plates. The LOPAC mixture plate was screened in the Akt-2 coupled assay using standard reaction conditions as described above. As shown in Figure 8 , the average ∆mP value was around 157. The negative control, determined with complete reactions in the presence of 10 µM staurosporine was 51, and the average positive control (complete reactions without inhibitor) was 208. The Z′ factor was calculated to be 0.73. The Z′ assesses the quality of the assay for HTS. 27 These results using IMAP demonstrate that this format is suitable for developing coupled as-says, allowing reliable and consistent results when compared with other assay formats.
IC 50 values for reference compounds
The reference compound staurosporine was tested in the Akt-2 coupled assay in both IMAP and the radioactive flashplate transfer assay formats. Optimal amounts of reaction components were Signal stability: 30 min versus overnight reading. Effect of miniaturization of the detection volume on the ∆mP for the coupled assay and the stability of the signal were determined. Coupled assay using optimal reactions was carried out, and different volumes of 2× beads in binding buffer were added to stop the reaction as described above. The plates were read after a 30-min incubation and then read again the following day after overnight incubation. used for the assays, and the dose-response curve for staurosporine (starting from 10 µM with 10-fold dilutions across the plate) was determined. The negative control was the optimal reaction in the presence of 10 µM staurosporine, and this mP value was used for calculating the total ∆mP values. IC 50 values were calculated using GraphPad Prism. Results shown in Figure 9A , B indicate that the IC 50 value for staurosporine in the coupled assay using IMAP and radioactive transfer assay formats was comparable, and the value in both assays was around 2 to 3 nM.
CONCLUSIONS
Protein kinases function in a large number of distinct signaling pathways in which tight regulation of their catalytic activity is crucial to the development and maintenance of eukaryotic organisms. The complexity and number of protein kinases being used as molecular targets in drug discovery have greatly increased. Targeting the catalytic site of kinases with ATP-competitive inhibitors appears to be the most promising approach for drug intervention, although 2 major obstacles need to be overcome: access to the intracellular targets and selectivity of inhibition. Considering the fact that there are~500 protein kinases, it is not surprising that selectivity has proven to be the more difficult of the 2 problems. 1, 2 Protein kinases are molecular switches that can adopt at least 2 extreme conformations: an "on" state that is maximally active and an "off" state that has minimal activity. All protein kinases upon activation adopt catalytically active "on" conformations that are structurally very similar because they all catalyze the same reaction, the transfer of the γ-phosphate of ATP to the hydroxyl group of serine, threonine, or tyrosine. The "off" state of protein kinases is not subject to the chemical constraints that the active states must satisfy, and so different classes of kinases have evolved distinct "off" states in which the adoption of the catalytic active conformation is impeded in different ways. The ability of the activation loops of different kinases to adopt distinct conformations when the kinase is "off" has recently been exploited in drug development. Gleevec (imatinib or STI571) binds to an inactive form of Abl kinase selectively, stabilizing the activation loop in a conformation that cannot be activated. 13 The closely related Src family kinases display an entirely different activation loop conformation in their inactive states and do not bind Gleevec despite close sequence similarity within the nucleotide recognition pocket. 28, 29 Thus, the specific binding of Gleevec to Abl and not to Src depends on the subtle sequence differences and the resulting conformational differences of the activation loop. Therefore, an alternate strategy for inhibiting a select protein kinase is to target its inactive state so as to prevent its activation by the upstream kinase and block its function.
The coupled assay described here using IMAP technology is a sensitive, robust, nonseparation assay that has the potential to identify different classes of inhibitors that would be useful from a therapeutic point of view. Figure 10 pounds that (1) inhibit PDK1 activity, (2) bind to the inactive conformation of a kinase (Akt-2) and prevent its activation by the upstream kinase (PDK1), and (3) inhibit the activity of the target kinase (Akt-2) that is activated. In addition to finding compounds that target the ATP binding site, ones that bind to the allosteric site of Akt in its inactive conformation and block activation/ phosphorylation by PDK1 can also be identified in this assay. Hence, the compounds that are scored as positives in the coupled assay need to be evaluated separately against PDK1 and activated Akt-2 kinases to sort out their inhibitory activities. Thus, kinase assays using active PDK1 and Akt-2 enzymes with appropriate biotinylated or fluorescein-labeled peptide substrates can be used to identify inhibitors that target the active enzymes. An in vitro phosphorylation reaction using PDK1 and inactive Akt-2, followed by western blot analysis using phospho-(Thr 308)-specific Akt antibodies, can be used to identify compounds that target the inactive Akt-2 enzyme and inhibit activation/phosphorylation by PDK1. The main advantage of this coupled assay over traditional kinase assays using single enzymes is that this assay can identify compounds that target the inactive enzyme and block activation by the upstream kinase.
